PharmaResearch Co., Ltd.

As of March 31, 2026, PharmaResearch Co., Ltd. carries a market capitalization of 3.11T, placing it among publicly traded companies globally. Its enterprise value stands at 2.52T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmaResearch Co., Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, PharmaResearch Co., Ltd. has 10.39M shares outstanding.

As of March 31, 2026, PharmaResearch Co., Ltd. trades at a trailing price-to-earnings ratio of 17.60. The price-to-sales ratio is 5.49, and the price-to-book ratio stands at 4.46.

As of March 31, 2026, PharmaResearch Co., Ltd. trades at an EV/EBITDA multiple of 10.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. PharmaResearch Co., Ltd. trades at an EV/FCF ratio of 16.56, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.52T versus a market cap of 3.11T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, PharmaResearch Co., Ltd. maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.26, indicating moderate leverage, while an interest coverage ratio of 45.79 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, PharmaResearch Co., Ltd. posted a return on equity (ROE) of 27.99, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 24.52 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.88, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 26.10, useful for judging operating efficiency across full business cycles. The company generates approximately 1.18B in revenue per employee across its workforce of 481.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.80 indicates how many times PharmaResearch Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, PharmaResearch Co., Ltd. recorded 57.61B in income tax expense. That works out to an effective tax rate of 24.15, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 238.59B, leaving 176.52B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, PharmaResearch Co., Ltd.'s stock has declined approximately 57.54% over the past 52 weeks. The 50-day moving average sits at 348,640.00, while the 200-day moving average is 345,330.00.

Over the twelve months ended March 31, 2026, PharmaResearch Co., Ltd. generated 565.48B in revenue and converted that into 176.52B in net income, yielding earnings per share of 15,648.29. EBITDA reached 243.19B, while operating income came in at 227.23B.

As of March 31, 2026, PharmaResearch Co., Ltd. holds 630.78B in cash and equivalents against 9.25B in total debt, resulting in a net debt position of -198.11B. Total book value stands at 696.90B, with working capital of 649.51B providing operational flexibility.

PharmaResearch Co., Ltd. produced 178.90B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -30.75B in capital expenditures, free cash flow totaled 148.16B - equivalent to 14,259.95 per share.

Over the twelve months ended March 31, 2026, PharmaResearch Co., Ltd. posted a gross margin of 77.58, reflecting its pricing power and cost economics. The operating margin of 40.18 and net profit margin of 31.22 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, PharmaResearch Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.28, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.58, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmaResearch Co., Ltd. shareholders.

As of March 31, 2026, PharmaResearch Co., Ltd. has an Altman Z-Score of 7.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.